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 Context
Migraine presents an important social, economic and disability 
burden in 14% of affected population.1 The age range more 
compromised is under 50, which represents a burden in personal, 
social and working functioning.1
Migraine treatments are old and with low compliance by the 
patient for adverse events. Erenumab is a fully human mono-
clonal antibody that inhibits the calcitonin gene-related peptide 
receptor (CGRPr) showing promising evidences from a controlled 
trial in episodic migraine.2
Methods
This randomised, double-blind, multicentre, placebo-controlled 
trial of erenumab in episodic migraine has been carried out 
through the monthly subcutaneous administration of either 
erenumab or placebo for a 6-month period. In total, 955 patients 
with episodic migraine were divided into three subgroups numer-
ically homogeneous, assigned to erenumab 70 mg, erenumab 
140 mg and placebo. Primary endpoint was baseline change in the 
mean number of migraine days per month, from the fourth to the 
sixth month of therapy.
The secondary outcomes were a reduction in migraine days 
per month of 50%, a change in the number of days in which 
migraine-specific medications were taken and a change in the 
scores of the test Migraine Physical Function Impact Diary in the 
specific domains physical impairment and everyday activities.
Findings
The randomised controlled trial (RCT) reported a reduction in mean 
migraine days per month during the last three months of treatment 
of 3.2 days in the erenumab 70 mg group, 3.7 days in the erenumab 
140 mg and 1.8 days in the placebo group (p<0.001). The same time 
comparison from baseline to the last three months of treatment has 
seen a reduction of at least 50% in mean migraine days per month. 
The mean number of days in which acute medication was taken was 
reduced of 1.1 days in the erenumab 70 mg and 1.6 in the erenumab 
140 mg  groups, while in the placebo group the reduction was of 
0.2 days (p<0.001). The evaluation of both dosages of erenumab on 
patient-reported physical functioning (MPFID) has seen a reduction 
from baseline scores of 5.5 in erenumab 70 mg and 5.9 in erenumab 
140 mg compared with the 3.3 of placebo. MPFID-PI scores resulted 
in reduction of 4.2 in erenumab 70 mg and 4.8 in erenumab 140 mg, 
compared with the 2.4 of placebo (p<0.001).
The percent rate of adverse events, although numerically elevated 
(55.5, 57.3 and 63.0, respectively, for erenumab 70 mg, 140 mg and 
placebo), reported no serious safety concerns in all groups, especially 
with no impact on hepatic function testing.
Commentary
This trial confirms the efficacy of erenumab in the preventive 
treatment of migraine through its action of monoclonal antibody 
towards CGRPr. Clinical improvement and the reduction of the 
frequency of migraine days are accompanied by a parallel reduc-
tion of acute migraine medication, and by a positive effect on 
the physical functioning of these patients. The safety throughout 
the 6-month treatment period with both doses of erenumab was 
very high, with no cardiovascular or hepatic risks. It is clear that 
RCTs present clean and clear patients, and only a future evalua-
tion of real-world patients undergoing multiple treatments can 
give further strength to these data.3 On the other hand, only the 
prolonged use of these drugs will show an absolute safety in the 
clinical daily practice.4 5
Implications for practice
We are on the edge of a new therapeutic migraine era. We have to 
understand if this therapy is applicable to any stage of migraine 
or, like it has been reasonably assumed, it will be directed predom-
inantly to pre-chronic form in order to avoid chronicity that seems 
to be today the real scourge of this global disease.3 Next targets 
are the comprehension of the interactions between erenumab and 
acute available drugs such as triptans6 and the application of 
personalised medicine in driving these therapeutic choices.7
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